What is the recommended treatment for mitral annular calcification (MAC) detected on echocardiography?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Mitral Annular Calcification Detected on Echocardiography

Treatment for MAC detected on echo should be individualized based on symptom severity, degree of mitral valve dysfunction, MAC extent, and patient surgical risk—with asymptomatic or mildly symptomatic patients managed conservatively with guideline-directed medical therapy and cardiovascular risk factor control, while symptomatic patients with significant valve dysfunction require multidisciplinary heart team evaluation to determine candidacy for surgical repair/replacement (using "Resect" or "Respect" techniques), transcatheter mitral valve replacement (TMVR), or hybrid approaches. 1

Initial Assessment and Risk Stratification

When MAC is detected on echocardiography, the first critical step is determining whether intervention is needed at all:

  • Asymptomatic or mildly symptomatic patients (NYHA class I-II) with significant mitral valve disease and severe MAC should have intervention risks carefully weighed against watchful waiting and guideline-directed medical therapy 1
  • No specific medical therapy exists to prevent MAC progression—treatment focuses on controlling cardiovascular risk factors 1
  • MAC represents a systemic disease process; long-term outcomes depend on overall disease burden regardless of valve repair 1

Who Should NOT Be Intervened Upon

Avoid intervention in patients with:

  • Limited life expectancy from non-cardiac pathologies
  • End-stage organ dysfunction (chronic lung disease, high MELD score liver disease)
  • Marked frailty
  • Poor functional/nutritional status
  • Poor social support 1

Critical pitfall: High periprocedural mortality rates (up to 20% in-hospital in some TMVR series) and poor midterm outcomes (69% one-year survival in multicenter studies) underscore the importance of careful patient selection 1

Mandatory Pre-Intervention Workup

All patients being considered for intervention require:

  1. Multidisciplinary heart team evaluation (Class I recommendation) including cardiac surgeon and structural heart cardiologist 1
  2. CT imaging (Class I) to assess MAC extent, distribution, and guide operative planning—echocardiography alone is insufficient 1
  3. Transesophageal echocardiography (Class I) for all transcatheter or hybrid intervention candidates 1
  4. Right heart catheterization (Class IIa) for hemodynamic assessment 1

Important caveat: STS risk scores do not fully capture surgical risk in MAC patients—heart team evaluation is essential 1

Treatment Algorithm Based on Risk and Anatomy

Low-Risk Patients with Mild-Moderate MAC

  • Conventional surgical mitral valve repair or replacement using "Resect" strategies (Class IIa) 1
  • En bloc annular decalcification with complete calcium bar excision
  • Atrioventricular groove reconstruction with pericardial patch or sliding atrioventriculoplasty
  • Freedom from reintervention exceeds 95% at 8 years with aggressive technique 1

High-Risk Patients with Moderate MAC

  • Conventional surgery using "Respect" strategies (Class IIa) 1
  • Limited or no calcium resection
  • Sutures placed around/through calcium bar
  • Oversized annuloplasty techniques
  • Intraleaflet prosthesis implantation

High-Risk Patients with Severe MAC

  • TMVR or Hybrid TMVR (Class IIa) with multidisciplinary approach 1
  • Recent SUMMIT-MAC trial data shows 60.4% freedom from death/HF hospitalization at 12 months with Tendyne system (significantly better than performance goal of 43%, p=0.0002) 2
  • Technical success 94.2%, 30-day mortality 6.8% 2
  • Significant symptom improvement: 87.5% achieved NYHA class I/II at 12 months vs 30.6% at baseline 2

Repair vs Replacement Decision

Mitral valve replacement should be considered over repair (Class IIa) in patients with: 1

  • Extensive MAC
  • Infected MAC
  • Severe mitral stenosis

Mitral valve repair is reasonable (Class IIa) in non-extensive MAC with repairable anatomy (preserved leaflet pliability, limited calcification extension) 1

Technical Considerations for Surgery

Adjunctive Techniques

  • Ultrasonic debridement (Sonopet or CUSA devices) may facilitate suture placement and prosthesis seating (Class IIb) 1
  • Chordal-sparing techniques should be implemented (Class I) while avoiding interference with prosthetic function 1
  • Felt strip reinforcement may reduce paravalvular leak risk 1

Special Anatomic Scenarios

  • Aortomitral curtain involvement (circumferential MAC, radiation-induced) often requires curtain reconstruction with concomitant aortic valve replacement or root procedure (Class IIa) 1

Pulmonary Hypertension Considerations

Pulmonary hypertension should not be considered an absolute contraindication to intervention 1. Contemporary data with new pulmonary vasodilators shows acceptable perioperative mortality in severe pulmonary hypertension, though careful preoperative evaluation and perioperative management are warranted 1.

Evidence Quality Note

The 2025 AATS expert consensus document 1 represents the most current and comprehensive guidance, though most recommendations carry Class IIa/IIb with Level C evidence, reflecting the challenging nature of this condition and limited high-quality data. The SUMMIT-MAC trial 2 provides the first prospective data supporting TMVR in this population, showing mortality benefit compared to historical controls.

References

Related Questions

What does severe mitral annular calcification (MAC) on echocardiography indicate about the mitral valve?
In a patient with asymmetric septal hypertrophy, impaired left ventricular relaxation, mild aortic valve sclerosis without significant stenosis, and mild mitral annular calcification, what is the next recommended step and which medication should be initiated?
How should calcific mitral valve leaflets be evaluated and managed?
What is the correct ICD‑10‑CM code for the primary valve lesion in a 71‑year‑old patient with preserved left ventricular ejection fraction, mild concentric left‑ventricular hypertrophy, grade I diastolic dysfunction, mild left‑atrial and right‑atrial dilation, mild mitral regurgitation with mitral annular calcification, mild tricuspid regurgitation, and a mildly calcified aortic valve with significant aortic stenosis and trivial aortic regurgitation, without pulmonary hypertension?
What is the clinical significance and recommended management of falcine calcification?
How long should rivaroxaban be held before a dilation and curettage in an adult female with normal renal function and no other bleeding risk?
Is it safe to start mirtazapine after being off Latuda (lurasidone) for 23 days?
What exercise regimen is recommended for a patient with symptomatic obstructive hypertrophic cardiomyopathy?
How should a patient with a borderline prolonged QT interval and a possible anteroseptal myocardial infarction be managed?
How should a patient with a left ventricular outflow tract (LVOT) gradient of 60 mm Hg be managed?
Is a liver detox recommended before initiating hormone replacement therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.